Individual ingredients of NP-101 (Thymoquinone formula) inhibit SARS-CoV-2 pseudovirus infection

Abdelrahim Maen; Betul Gok Yavuz; Yehia I. Mohamed; Abdullah Esmail; Jianming Lu; Amr Mohamed; Asfar S. Azmi; Mohamed Kaseb; Osama Kasseb; Dan Li; Michelle Gocio; Mehmet Kocak; Abdelhafez Selim; Qing Ma; Ahmed O. Kaseb

doi:10.3389/fphar.2024.1291212

Individual ingredients of NP-101 (Thymoquinone formula) inhibit SARS-CoV-2 pseudovirus infection

Abdelrahim Maen, Betul Gok Yavuz, Yehia I. Mohamed, Abdullah Esmail, Jianming Lu, Amr Mohamed, Asfar S. Azmi, Mohamed Kaseb, Osama Kasseb, Dan Li, Michelle Gocio, Mehmet Kocak, Abdelhafez Selim, Qing Ma, Ahmed O. Kaseb

Research output: Contribution to journal › Article › peer-review

Abstract

Thymoquinone TQ, an active ingredient of Nigella Sativa, has been shown to inhibit COVID-19 symptoms in clinical trials. Thymoquinone Formulation (TQF or NP-101) is developed as a novel enteric-coated medication derivative from Nigella Sativa. TQF consists of TQ with a favorable concentration and fatty acids, including palmitic, oleic, and linoleic acids. In this study, we aimed to investigate the roles of individual ingredients of TQF on infection of SARS-CoV-2 variants in-vitro, by utilizing Murine Leukemia Virus (MLV) based pseudovirus particles. We demonstrated that NP-101, TQ, and other individual ingredients, including oleic, linoleic, and palmitic acids inhibited SARS-CoV-2 infection in the MLV-based pseudovirus model. A large, randomized phase 2 study of NP-101 is planned in outpatient COVID-19 patients.

Original language	English (US)
Article number	1291212
Pages (from-to)	1291212
Journal	Frontiers in Pharmacology
Volume	15
DOIs	https://doi.org/10.3389/fphar.2024.1291212 https://doi.org/10.3389/fphar.2024.1291212
State	Published - 2024

Keywords

COVID-19
COVID-19 and anti-viral agents
Coronavirus
TQ formula
Thymoquinone TQ
fatty acids

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Access to Document

Cite this

Maen, A., Gok Yavuz, B., Mohamed, Y. I., Esmail, A., Lu, J., Mohamed, A., Azmi, A. S., Kaseb, M., Kasseb, O., Li, D., Gocio, M., Kocak, M., Selim, A., Ma, Q., & Kaseb, A. O. (2024). Individual ingredients of NP-101 (Thymoquinone formula) inhibit SARS-CoV-2 pseudovirus infection. Frontiers in Pharmacology, 15, 1291212. Article 1291212. https://doi.org/10.3389/fphar.2024.1291212, https://doi.org/10.3389/fphar.2024.1291212

Maen, A, Gok Yavuz, B, Mohamed, YI, Esmail, A, Lu, J, Mohamed, A, Azmi, AS, Kaseb, M, Kasseb, O, Li, D, Gocio, M, Kocak, M, Selim, A, Ma, Q & Kaseb, AO 2024, 'Individual ingredients of NP-101 (Thymoquinone formula) inhibit SARS-CoV-2 pseudovirus infection', Frontiers in Pharmacology, vol. 15, 1291212, pp. 1291212. https://doi.org/10.3389/fphar.2024.1291212, https://doi.org/10.3389/fphar.2024.1291212

@article{9bcac67511b242e29ddbbe84e8f9dde8,

title = "Individual ingredients of NP-101 (Thymoquinone formula) inhibit SARS-CoV-2 pseudovirus infection",

abstract = "Thymoquinone TQ, an active ingredient of Nigella Sativa, has been shown to inhibit COVID-19 symptoms in clinical trials. Thymoquinone Formulation (TQF or NP-101) is developed as a novel enteric-coated medication derivative from Nigella Sativa. TQF consists of TQ with a favorable concentration and fatty acids, including palmitic, oleic, and linoleic acids. In this study, we aimed to investigate the roles of individual ingredients of TQF on infection of SARS-CoV-2 variants in-vitro, by utilizing Murine Leukemia Virus (MLV) based pseudovirus particles. We demonstrated that NP-101, TQ, and other individual ingredients, including oleic, linoleic, and palmitic acids inhibited SARS-CoV-2 infection in the MLV-based pseudovirus model. A large, randomized phase 2 study of NP-101 is planned in outpatient COVID-19 patients.",

keywords = "COVID-19, COVID-19 and anti-viral agents, Coronavirus, TQ formula, Thymoquinone TQ, fatty acids",

author = "Abdelrahim Maen and {Gok Yavuz}, Betul and Mohamed, {Yehia I.} and Abdullah Esmail and Jianming Lu and Amr Mohamed and Azmi, {Asfar S.} and Mohamed Kaseb and Osama Kasseb and Dan Li and Michelle Gocio and Mehmet Kocak and Abdelhafez Selim and Qing Ma and Kaseb, {Ahmed O.}",

note = "Copyright {\textcopyright} 2024 Maen, Gok Yavuz, Mohamed, Esmail, Lu, Mohamed, Azmi, Kaseb, Kasseb, Li, Gocio, Kocak, Selim, Ma and Kaseb.",

year = "2024",

doi = "10.3389/fphar.2024.1291212",

language = "English (US)",

volume = "15",

pages = "1291212",

journal = "Frontiers in Pharmacology",

issn = "1663-9812",

publisher = "Frontiers Media S. A.",

}

TY - JOUR

T1 - Individual ingredients of NP-101 (Thymoquinone formula) inhibit SARS-CoV-2 pseudovirus infection

AU - Maen, Abdelrahim

AU - Gok Yavuz, Betul

AU - Mohamed, Yehia I.

AU - Esmail, Abdullah

AU - Lu, Jianming

AU - Mohamed, Amr

AU - Azmi, Asfar S.

AU - Kaseb, Mohamed

AU - Kasseb, Osama

AU - Li, Dan

AU - Gocio, Michelle

AU - Kocak, Mehmet

AU - Selim, Abdelhafez

AU - Ma, Qing

AU - Kaseb, Ahmed O.

PY - 2024

Y1 - 2024

N2 - Thymoquinone TQ, an active ingredient of Nigella Sativa, has been shown to inhibit COVID-19 symptoms in clinical trials. Thymoquinone Formulation (TQF or NP-101) is developed as a novel enteric-coated medication derivative from Nigella Sativa. TQF consists of TQ with a favorable concentration and fatty acids, including palmitic, oleic, and linoleic acids. In this study, we aimed to investigate the roles of individual ingredients of TQF on infection of SARS-CoV-2 variants in-vitro, by utilizing Murine Leukemia Virus (MLV) based pseudovirus particles. We demonstrated that NP-101, TQ, and other individual ingredients, including oleic, linoleic, and palmitic acids inhibited SARS-CoV-2 infection in the MLV-based pseudovirus model. A large, randomized phase 2 study of NP-101 is planned in outpatient COVID-19 patients.

AB - Thymoquinone TQ, an active ingredient of Nigella Sativa, has been shown to inhibit COVID-19 symptoms in clinical trials. Thymoquinone Formulation (TQF or NP-101) is developed as a novel enteric-coated medication derivative from Nigella Sativa. TQF consists of TQ with a favorable concentration and fatty acids, including palmitic, oleic, and linoleic acids. In this study, we aimed to investigate the roles of individual ingredients of TQF on infection of SARS-CoV-2 variants in-vitro, by utilizing Murine Leukemia Virus (MLV) based pseudovirus particles. We demonstrated that NP-101, TQ, and other individual ingredients, including oleic, linoleic, and palmitic acids inhibited SARS-CoV-2 infection in the MLV-based pseudovirus model. A large, randomized phase 2 study of NP-101 is planned in outpatient COVID-19 patients.

KW - COVID-19

KW - COVID-19 and anti-viral agents

KW - Coronavirus

KW - TQ formula

KW - Thymoquinone TQ

KW - fatty acids

UR - http://www.scopus.com/inward/record.url?scp=85185316688&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85185316688&partnerID=8YFLogxK

U2 - 10.3389/fphar.2024.1291212

DO - 10.3389/fphar.2024.1291212

M3 - Article

C2 - 38379905

SN - 1663-9812

VL - 15

SP - 1291212

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

M1 - 1291212

ER -

Individual ingredients of NP-101 (Thymoquinone formula) inhibit SARS-CoV-2 pseudovirus infection

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this